EMEA-002431-PIP01-18
Key facts
Invented name |
Alecensa
|
Active substance |
Alectinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0359/2018
|
PIP number |
EMEA-002431-PIP01-18
|
Pharmaceutical form(s) |
Capsule, hard
|
Condition(s) / indication(s) |
Treatment of non-small cell lung carcinoma (NSCLC)
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|